In this regard, Schett and colleagues have evaluated CD19 CAR T‐cell therapy in eight patients with systemic lupus erythematosus (SLE), three with idiopathic inflammatory myositis (IIM), and four with systemic sclerosis (SSc) (Figure 1). The gene discussed is CD19; the disease is systemic sclerosis.